Lincoln National Corporation’s Board of Directors Declares Series C and Series D Preferred Stock Dividends

RADNOR, Pa.--(BUSINESS WIRE)-- Lincoln Financial (NYSE: LNC) announced today that the board of directors of Lincoln National Corporation has declared the following preferred stock dividends:

• Semi-annual dividend of $1,156.25 per share on the corporation’s 9.250% Fixed Rate Reset Non-Cumulative Preferred Stock, Series C, $25,000 liquidation preference per share, represented by depositary shares each representing a 1/25th interest in a share of the preferred stock, holders of which will receive $46.25 per share.
• Quarterly dividend of $562.50 per share on the corporation’s 9.000% Non-Cumulative Preferred Stock, Series D, $25,000 liquidation preference per share, represented by depositary shares each representing a 1/1,000th interest in a share of the preferred stock, holders of which will receive $0.5625 per depositary share (NYSE: LNC PRD).

The above dividends will be payable September 1, 2026 to holders of record on August 17, 2026.

About Lincoln Financial

Lincoln Financial helps people confidently plan for their vision of a successful financial future. As of December 31, 2025, approximately 17 million customers trust our guidance and solutions across four core businesses – annuities, life insurance, group protection, and retirement plan services. As of June 30, 2026, the company had $366 billion in end-of-period account balances, net of reinsurance. Headquartered in Radnor, PA., Lincoln Financial is the marketing name for Lincoln National Corporation (NYSE: LNC) and its affiliates. Learn more at LincolnFinancial.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260731698501/en/

John Muething
Investor Relations
[email protected]

Karyn Baldwin
Media Relations
[email protected]

Source: Lincoln Financial

You May Also Be Interested In

• Swiss Firms Advance AI Governance in Work Strategies
• Calla Lily Clinical Care Selected to Join Wellcome Leap’s $50M Focused Antibiotics Programme
• PsiQuantum Appoints Niklas Zennström to Board of Directors